Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.63 |
| ▸ | DPP4 | P27487 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.63 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.63 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.63 |
| ▸ | GAPDH | P04406 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | STAT6 | P42226 | 1/20 | 0.63 |
| ▸ | PI4KA | P42356 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.63 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.63 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.63 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21837298 | 1.00 | ADORA3 (0.63) | ADORA3ADORA2AADORA2BADORA1KMT2A | |
| SCHEMBL800618 | 1.00 | ADORA3 (0.63) | ADORA3ADORA2AADORA2BADORA1KMT2A | |
| SCHEMBL21413842 | 1.00 | ADORA3 (0.63) | ADORA3ADORA2AADORA2BADORA1KMT2A | |
| SCHEMBL21837300 | 0.91 | EHMT1 (0.62) | ADORA3ADORA2AADORA2BADORA1KMT2A | |
| SCHEMBL18055826 | 0.91 | EHMT1 (0.62) | ADORA3ADORA2AADORA2BADORA1KMT2A | |
| SCHEMBL18026183 | 0.91 | EHMT1 (0.62) | ADORA3ADORA2AADORA2BADORA1KMT2A | |
| SCHEMBL18026190 | 0.91 | EHMT1 (0.62) | ADORA3ADORA2AADORA2BADORA1KMT2A | |
| SCHEMBL18055969 | 0.91 | ADORA3 (0.58) | ADORA3ADORA2AADORA2BADORA1KMT2A | |
| SCHEMBL30786566 | 0.90 | EGFR (0.65) | ADORA3ADORA2AADORA2BADORA1KMT2A | |
| SCHEMBL30786564 | 0.90 | ADORA3 (0.54) | ADORA3ADORA2AADORA2BADORA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3262057-B1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2020-04-15 | — | — | EP | disclosed |
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| WO-2016135582-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | TYMP, NME1, DPYD | ADORA3 1160/4885ADORA2A 508/4885ADORA2B 1429/4885 |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | TYMP, NME1, PNP | ADORA3 1149/4885ADORA2A 631/4885ADORA2B 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.